Addressing Neuromuscular Deficits for Improved Outcomes in Ankle Rehabilitation
Launched by PHILLIP GRIBBLE · Sep 5, 2018
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new type of rehabilitation program called the SMART protocol to help people recover from lateral ankle sprains (LASs). The goal is to see if this new method is better than the standard care currently provided. Researchers want to find out if the SMART protocol leads to better recovery outcomes after a year, reduces the chances of re-injuring the ankle, and improves overall health for patients.
To participate in this study, individuals aged 65 to 70 who have recently experienced their first ankle sprain and are starting rehabilitation within 72 hours may be eligible. However, those with certain medical conditions, like a history of seizures or heart disease, will not be able to join. If selected, participants can expect to follow the new training program and help researchers understand how effective it is compared to traditional methods. This trial aims to provide valuable insights into ankle sprain recovery and improve rehabilitation practices in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • initiating rehabilitation for a first time acute grade I, II, or III LAS
- • have sustained within 72 hours of study enrollment
- • diagnosed by a physician, medic, athletic trainer, physical therapist, or other providing medical coverage in operational environments as having sustained a LAS
- Exclusion Criteria:
- • personal or familial history of epilepsy or seizures
- • history of migraine headaches
- • ocular foreign body, increased intracranial pressure, open head injury or significant closed head injury
- • cochlear implants
- • implanted brain stimulators, aneurysm clips or other metal in the head (except mouth)
- • implanted medication pumps, pacemakers or intracardiac lines
- • current medication with tricyclic anti-depressants, neuroleptic agents or other drugs that lower seizure threshold
- • history of diagnosed major psychiatric disorder
- • history of illicit drug use
- • current alcohol abuse or currently withdrawing from alcohol abuse
- • history of heart disease
About Phillip Gribble
Phillip Gribble is a distinguished clinical trial sponsor dedicated to advancing healthcare through innovative research and development. With a strong emphasis on collaboration and scientific rigor, the organization specializes in conducting high-quality clinical trials that aim to evaluate new therapeutics and medical interventions. Committed to ethical standards and patient safety, Phillip Gribble fosters partnerships with leading academic institutions and industry stakeholders to drive the discovery of effective treatments. Their comprehensive approach to clinical research ensures that they remain at the forefront of medical advancements, ultimately improving patient outcomes and enhancing the quality of care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chapel Hill, North Carolina, United States
Lexington, Kentucky, United States
El Paso, Texas, United States
Patients applied
Trial Officials
Phillip Gribble, PhD
Principal Investigator
University of Kentucky
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials